“To overcome elusive ROI figures on electronic medical record projects, vendors have been touting the value of digitized data for secondary uses such as drug recall notification and post-release pharmaceutical studies.
But as a panel of experts assembled in the nation’s capital pointed out on Monday, calling those applications “secondary” betrays a limiting perspective on technology.”
Article
Jack Beaudoin, Healthcare IT News, 6 May 2008
